Kazuki Nozawa, MD 野澤先生、コメントありがとうございます。Angiopep-2ペプチドは、LRP1を介した受容体介在性トランスサイトーシスを利用してBBBを通過する能力を持つペプチドです。

Here's the most recent #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (July 4th-July 11th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

🔴Online now: HER2DX and survival outcomes in early-stage HER2-positive #breastcancer: an individual patient-level meta-analysis Authors: @prat_aleix, Sara Tolaney, and Guillermo Villacampa thelancet.com/journals/lanon…

Expected pathological complete response rates in early stage II/III HER2+ breast cancer. #bcsm Dana-Farber’s Breast Oncology Center

Dr. Jennifer Ligibel closed out Day 1 of the #HarvardBreastCancerCourse with a special lecture on lifestyle, diet and exercise in #BreastCancer patients, touching on hot topics such as the #ChallengeTrial, #GLP1s and #weightloss.

Dr. Paolo Tarantino (Paolo Tarantino) discussed emerging #AntibodyDrugConjugates in ER+ #BreastCancer providing a look at exciting agents redefining the future of endocrine-resistant disease. #HarvardBreastCancerCourse

非常に興味深いADC総説を分かりやすくまとめてくれて、ありがたい限りです！必読！

Here's the most recent #BreastCancer Research Digest-a summary of last week’s publications from select high-impact journals (July 11th-18th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Excited to share our latest publication from the EN-SEMBLE study in ESMO Open! ESMO Open Post-T-DXd therapy is a major unmet need in HER2+ mBC. This large, real-world study provides insights into treatment patterns, outcomes, and the risk of ILD. 👉 doi.org/10.1016/j.esmo…

🏁latest review from #loilab & our Spanish colleagues #vhio #bcsm OncoAlert TILs Working Group Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer thebreastonline.com/article/S0960-…

Results from VIKTORIA-1 just announced by Celcuity. The addition of gedatolisib to 2L fulvestrant/palbo improved PFS from 2 to 9.3 months (HR 0.24). Also the fulvestrant/gedatolisib combo improved PFS vs fulv mono (7.4 vs 2 mo, HR 0.33). Quite promising. morningstar.com/news/globe-new…

Great retrospective study on post-T-DXd outcomes for HER2+ mBC — congrats Kazuki Nozawa, MD!

Multiple ADCs have outperformed chemo for treating mBC. Yet their most transformative impact is expected in the curative setting. DB11 will report at #ESMO25 & much more is coming. We review the field in our latest NPJ Breast review, led by Pooja Patel. nature.com/articles/s4152…

日本ではトルカプを使うための遺伝子検査に課題がありますが、ようやく迅速コンパニオン診断ができるようになりそうです。 Thermo Fisher Japan has applied for regulatory approval for a new companion diagnostic system for Capivasertib! thermofisher.com/jp/ja/home/abo…

Highly recommended weekend reading from Paolo Tarantino Dana-Farber’s Breast Oncology Center Dana-Farber’s Breast Oncology Center outlines expert guidance on datopotamab deruxtecan (Dato-DXd) in HR+/HER2- MBC. physicianresources.dana-farber.org/flexpaper/dato…

Top #BreastCancer Trials for July 2025, curated by LARVOL CLIN based on oncologist sentiment on 𝕏. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights |

PRIM-BC (JCOG1017) が7月中に世界で最も話題になった試験だったようです！ 素晴らしいです！Tadahiko Shien JCOG JCOGbreast

Here's the most recent #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (July 25th- August 1st, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Is there a synergistic effect between enfortumab vedotin (EV) and pembrolizumab (P) for untreated advanced urothelial carcinoma in clinical setting? This analysis suggests no! EV+P seems to follow a an independent drug action model with no evidence of synergy

One of the responsibilities in using new drugs and having that experience early is teaching how to best manage them once they broadly get to clinic and patients. Happy to participate in Delphi consensus on stomatitis with dato-DXd. #bcsm #TROP2 #ADC pubmed.ncbi.nlm.nih.gov/40762824/